DeepUll
- Company typePrivate
- Founded2019
- HeadquartersBarcelona, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
DeepUll firmographics
Firmographics- Name
- DeepUll
- Legal name
- DEEPULL DIAGNOSTICS, S.L.
- Website
- https://deepull.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
DeepUll industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Sepsis, Deterioration & Rapid Response CDS (HLACAGAF)
- akta.pro secondary industries
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)
Keywords
Where DeepUll is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
DeepUll business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
DeepUll product offering
Product offeringCore offering
DeepUll is developing the UllCORE diagnostic system, an automated sample-to-result platform that performs direct-from-blood multiplex PCR testing to detect pathogens and antibiotic resistance markers from whole blood in approximately one hour, targeting 95% of sepsis-causing pathogens. The intended customers are hospital laboratories and clinical care teams managing patients with suspected sepsis or bloodstream infections, with the product currently under clinical validation and not yet commercially available.
Product overview
DeepUll is developing a direct-from-blood multiplex PCR diagnostic system. The product portfolio consists of the UllCORE System, an automated sample-to-result platform, combined with the UllCORE BSI Test that detects over 50 reportable results identifying pathogens and antibiotic resistance markers directly from blood in about 1 hour. Together, these products target 95% of sepsis-causing pathogens to enable rapid diagnosis and therapy guidance for sepsis patients.
Differentiator
Problem solved
Functional benefit
Products and services
- UllCORE System
Quantifiable outcome
- Detects more than twice as many clinically relevant pathogens compared to blood culture
- +2 more outcomes
Companies that use DeepUll
Customer profileSegments3 records
Ideal customer profiles2 records
DeepUll technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
DeepUll partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
DeepUll competitors and assessment
Company assessmentDirect peers
- T2 Biosystems: Direct competitor developing direct-from-blood molecular diagnostics for sepsis and bloodstream infections (T2Bacteria, T2Candida), targeting the same hospital lab customer with culture-independent detection — the closest analog to DeepUll's UllCORE BSI Test.
- Accelerate Diagnostics: Develops rapid identification and antibiotic susceptibility testing (ID/AST) directly from positive blood cultures for bloodstream infections, addressing the same clinical decision point in the sepsis pathway as DeepUll's platform.
Broad incumbents
- bioMérieux: Global IVD leader whose BIOFIRE Blood Culture Identification (BCID2) panel is the established standard for rapid pathogen ID from positive blood cultures; DeepUll's direct-from-blood approach positions it as a workflow-disrupting alternative to bioMérieux's culture-dependent franchise.
- Becton Dickinson (BD): Major IVD incumbent with BD MAX molecular systems and microbiology workflows for bloodstream infections; DeepUll's chairman and an advisor are former BD executives, and BD's installed base represents both a competitive threat and a potential partnership target.
- Cepheid (Danaher): Operates the GeneXpert molecular diagnostics platform widely deployed in hospital labs, including Xpert Blood Culture panels — a competing sample-to-result workflow for bloodstream infection diagnostics.
- Roche Diagnostics: Diversified molecular diagnostics and clinical chemistry incumbent with broad hospital lab presence and sepsis-related assay portfolios; relevant as both a competitor and an acquirer with prior ties to DeepUll's advisory bench.
- Bruker: Offers MALDI Biotyper and MBT Sepsityper for microbial identification, including direct-from-blood workflows for sepsis diagnostics — an adjacent competing approach in bloodstream infection identification.
Emerging players
- Q-linea: Swedish developer of the ASTar rapid antibiotic susceptibility testing system for bloodstream infections; addresses an adjacent step in the same sepsis diagnostic workflow that DeepUll targets.
- Specific Diagnostics: Developer of rapid phenotypic AST for bloodstream infections using a metabolomic signature approach; competes in the same rapid sepsis/BSI decision-making window.
- Selux Diagnostics: Boston-based developer of rapid phenotypic AST for bloodstream infections targeting the same antibiotic-stewardship decision point in sepsis management that UllCORE's resistance-marker reporting aims to address.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
DeepUll social profiles
Digital presenceDeepUll compliance and trust
Trust signalCompliance1 record
DeepUll financial estimates
Financial estimateRevenue estimate
Valuation estimate
DeepUll leadership team
Management profileNumber of profiles
Profiles20 records
DeepUll funding detail
Funding detailFunding overview
Funding rounds5 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DeepUll M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DeepUll
What does DeepUll do?
DeepUll is developing the UllCORE diagnostic system, an automated sample-to-result platform that performs direct-from-blood multiplex PCR testing to detect pathogens and antibiotic resistance markers from whole blood in approximately one hour, targeting 95% of sepsis-causing pathogens. The intended customers are hospital laboratories and clinical care teams managing patients with suspected sepsis or bloodstream infections, with the product currently under clinical validation and not yet commercially available.
Is DeepUll a public or private company?
DeepUll is a private company. It is classified as venture growth investor backed and is currently operating.
When was DeepUll founded?
DeepUll was founded in 2019. It employs 11 to 50 people.
Where is DeepUll based?
DeepUll is headquartered in Barcelona, Spain, in the Europe region.
Who are DeepUll's main competitors?
Direct peers on record are T2 Biosystems and Accelerate Diagnostics. Broad incumbents are bioMérieux, Becton Dickinson (BD), Cepheid (Danaher), Roche Diagnostics and Bruker. Emerging players are Q-linea, Specific Diagnostics and Selux Diagnostics.
Does DeepUll have an API?
No public API is recorded for DeepUll.
What industry is DeepUll in?
DeepUll's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLACAGAF, Sepsis, Deterioration & Rapid Response CDS, with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 2835.